|1.||Zhang, Yan: 5 articles (09/2015 - 08/2010)|
|2.||Zhang, Feng: 4 articles (09/2015 - 09/2011)|
|3.||Haney, Kendra M: 4 articles (09/2012 - 08/2010)|
|4.||Arnatt, Christopher K: 3 articles (09/2012 - 09/2011)|
|5.||Ware, Joy L: 3 articles (09/2012 - 08/2010)|
|6.||Yuan, Yunyun: 2 articles (09/2015 - 09/2011)|
|7.||Richardson, Amanda C: 2 articles (09/2012 - 08/2010)|
|8.||Gewirtz, David A: 2 articles (09/2011 - 08/2010)|
|9.||Singh, Shilpa: 1 article (09/2015)|
|10.||Zaidi, Saheem A: 1 article (09/2015)|
|1.||Prostatic Neoplasms (Prostate Cancer)
09/01/2012 - "In order to refine the lead compound's structure and improve the therapeutic index of anibamine derivatives as potential anti prostate cancer agents, the approach of "deconstruction-reconstruction-elaboration" was applied in the structure-activity relationship studies of this work. "
08/01/2010 - "Our studies demonstrate that anibamine produces significant inhibition of prostate cancer cell proliferation at micromolar to submicromolar concentrations as well as suppressing adhesion and invasion of the highly metastatic M12 prostate cancer cell line. "
09/01/2015 - "Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents."
09/01/2012 - "Here, we report the design, syntheses and anti prostate cancer activities of anibamine and 17 analogues. "
09/15/2011 - "A series of analogs of anibamine were designed, synthesized and tested against several prostate cancer cell lines. "
08/01/2010 - "Preliminary in vivo studies indicate that anibamine also inhibits prostate tumor growth in mice. "
09/01/2015 - "Anibamine, a natural product containing a pyridine ring and two aliphatic side chains, was shown to carry a binding affinity of 1 μM at CCR5 as an antagonist with potential anti-cancer activity. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
08/01/2012 - "Based on these results, anibamine and one of its synthetic analogues were defined as potential leads to develop novel agents against ovarian cancer."
08/01/2012 - "Anibamine, the first natural product CCR5 antagonist, and its analogues were examined for their effects on proliferation of the OVCAR-3 ovarian cancer cells in order to validate their candidacy as leads to develop novel anti-ovarian cancer agents. "
08/01/2012 - "The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-ovarian cancer agents."
|1.||CCR5 Receptors (CCR5 Receptor)